Title

Ipilimumab activity in advanced uveal melanoma: A pooled analysis

Document Type

Journal Article

Publication Title

International Journal of Cancer and Clinical Research

Publisher

ClinMed International Library

School

School of Medical and Health Sciences

RAS ID

27349

Comments

Originally published as:

Khattak, M. A., & Gray, E. (2018). Ipilimumab activity in advanced uveal melanoma: A pooled analysis. International Journal of Cancer and Clinical Research, 4(2).

Original article available here.

Abstract

Background

Uveal Melanoma is a rare tumour that displays different clinical behavior and molecular features compared with cutaneous melanoma. It is generally resistant to systemic therapy and there is no current standard effective therapy to treat patients with advanced disease.

Patients and methods

We searched Medline, PubMed, EMBASE and major oncology conference abstracts from the past 5 years to identify relevant studies evaluating ipilimumab monotherapy in uveal melanoma. Data were extracted on ipilimumab dose, sample size, Objective Response Rate (ORR), Progression Free Survival (PFS), median Overall Survival (mOS), Disease Control Rate (DCR), 1 year Overall Survival (1yrOS) and 2 year Overall Survival (2yrOS).

Results

Nine studies were included in this study including Phase II clinical trials (n = 2), Expanded Access Programs (EAP) (n = 4) and retrospective studies (n = 3). Cases were a mix of pre-treated and treatment-naïve patients. Reported mOS ranged from 5.2-28 months (median: 9.3 months), and reported 1yrOS ranged between 4.5-65%. Calculated compound ORR was 3.4%, and compound DCR was 36%.

Conclusion

Ipilimumab has limited clinical activity in advanced uveal melanoma. Further research is needed to identify more effective systemic therapies for management of these patients.

DOI

10.23937/2378-3419/1410088

Access Rights

Free_to_read

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS